Bicocca Open Archive

Logo unimib boa
BIDOLI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.486
AS - Asia 6.212
EU - Europa 4.430
SA - Sud America 959
Continente sconosciuto - Info sul continente non disponibili 612
AF - Africa 135
OC - Oceania 12
Totale 23.846
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.557
SG - Singapore 2.364
IT - Italia 1.165
HK - Hong Kong 1.153
CN - Cina 1.123
CA - Canada 830
RU - Federazione Russa 820
BR - Brasile 704
IE - Irlanda 616
VN - Vietnam 539
DE - Germania 493
SE - Svezia 461
BD - Bangladesh 198
IN - India 198
GB - Regno Unito 187
FR - Francia 179
UA - Ucraina 123
FI - Finlandia 95
AR - Argentina 94
ID - Indonesia 77
TR - Turchia 76
AT - Austria 75
IQ - Iraq 74
JP - Giappone 61
PK - Pakistan 61
MX - Messico 48
SA - Arabia Saudita 46
PH - Filippine 43
CO - Colombia 39
DK - Danimarca 39
ZA - Sudafrica 39
ES - Italia 36
KR - Corea 36
VE - Venezuela 34
NL - Olanda 33
EC - Ecuador 31
PL - Polonia 25
UZ - Uzbekistan 25
BE - Belgio 19
JM - Giamaica 17
JO - Giordania 17
CL - Cile 14
NP - Nepal 14
PY - Paraguay 14
KE - Kenya 12
MA - Marocco 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
PE - Perù 11
TH - Thailandia 11
AU - Australia 10
EG - Egitto 10
MY - Malesia 9
DZ - Algeria 8
ET - Etiopia 8
IR - Iran 8
KZ - Kazakistan 8
TN - Tunisia 8
HN - Honduras 7
LB - Libano 7
RO - Romania 7
AZ - Azerbaigian 6
BO - Bolivia 6
SN - Senegal 6
AL - Albania 5
AM - Armenia 5
AO - Angola 5
BA - Bosnia-Erzegovina 5
BG - Bulgaria 5
IL - Israele 5
KG - Kirghizistan 5
MU - Mauritius 5
PS - Palestinian Territory 5
RS - Serbia 5
CR - Costa Rica 4
DO - Repubblica Dominicana 4
LT - Lituania 4
MN - Mongolia 4
NG - Nigeria 4
NI - Nicaragua 4
PA - Panama 4
TW - Taiwan 4
BY - Bielorussia 3
CH - Svizzera 3
CI - Costa d'Avorio 3
GA - Gabon 3
GR - Grecia 3
GT - Guatemala 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
BH - Bahrain 2
CG - Congo 2
CZ - Repubblica Ceca 2
EU - Europa 2
GE - Georgia 2
HU - Ungheria 2
IS - Islanda 2
Totale 23.198
Salva come PNG Salva come JPEG
Città #
Singapore 1.336
Ann Arbor 1.331
Hong Kong 1.116
Ashburn 1.026
Fairfield 850
Toronto 720
San Jose 629
Dublin 607
Woodbridge 482
Wilmington 436
Seattle 392
Chandler 372
Milan 350
Houston 333
Cambridge 321
New York 321
Frankfurt am Main 297
Princeton 250
Chicago 234
Beijing 222
The Dalles 217
Santa Clara 213
Council Bluffs 178
Jacksonville 171
Ho Chi Minh City 158
Los Angeles 157
Shanghai 136
Hanoi 125
Altamura 122
Lauterbourg 119
Lawrence 118
Dallas 115
Rome 111
Moscow 78
San Diego 73
Helsinki 68
Dearborn 63
São Paulo 56
Buffalo 51
Jakarta 51
Vienna 51
Boardman 45
Andover 44
Turin 41
London 40
Guangzhou 39
Tokyo 35
Baghdad 34
Nanjing 33
Hefei 32
Orem 32
Columbus 31
Rio de Janeiro 30
Salt Lake City 30
Hangzhou 29
Munich 29
Dhaka 28
Haiphong 28
Nuremberg 28
Washington 27
Pune 26
Ottawa 25
San Francisco 24
Falls Church 23
Da Nang 22
Dong Ket 22
Lahore 22
Seoul 22
Atlanta 21
Riyadh 21
Phoenix 20
Tashkent 20
Boston 19
Chennai 19
Naples 19
Brussels 18
Montreal 18
Norwalk 18
Johannesburg 17
Tianjin 17
Mumbai 16
Amman 15
Jinan 15
Tampa 15
Amsterdam 14
Brooklyn 14
Denver 14
Kingston 14
Warsaw 14
Brasília 13
Elk Grove Village 13
Hebei 13
Karachi 13
Redmond 13
Zhengzhou 13
Changsha 12
Guayaquil 12
Istanbul 12
Jeddah 12
Lachine 12
Totale 15.373
Salva come PNG Salva come JPEG
Nome #
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 456
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 414
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 412
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 403
Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab 401
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 379
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 347
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings 329
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 326
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 320
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 317
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 315
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 301
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 297
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 287
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 277
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 267
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 259
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial 258
When progressive dysphagia could be related to an “old friend” – a case report 248
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 245
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 244
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis 239
Novel cytotoxic chemotherapies in small cell lung carcinoma 225
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 223
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 223
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 216
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 214
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 211
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 210
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 208
Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer 206
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 204
Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin‐2 in advanced small cell lung cancer patients 203
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 203
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 203
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations 199
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial 198
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 198
Second-line erlotinib or intermittent erlotinib plus docetaxel in male ex-smokers with squamous NSCLC: The TALISMAN randomized trial 195
Focus on nivolumab in NSCLC 193
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 193
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 192
Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival 187
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial 186
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 186
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review 183
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial 179
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study 179
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 178
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial 178
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 178
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study 174
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer 173
Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer 173
Malignant mesothelioma in subjects with Marfan's syndrome and Ehlers-Danlos syndrome: only an apparent association? 173
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 172
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study 171
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial 171
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors 171
Esophageal squamous cell carcinoma: MRI evaluation of mediastinum 170
Drugs ten years later: epirubicin 167
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 164
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial 163
Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer 161
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 159
Antiemetic activity of metoclopramide versus alizapride during cancer chemotherapy 158
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 157
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer 157
Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma 156
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 155
Surgical resection in the treatment of stages I-II of small cell lung carcinoma (SCLC) 155
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial 154
Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis 153
Pilot study with adriamycin and ifosfamide in small cell lung cancer 153
Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity 151
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer 151
Prognosis after nonradical resections for small cell lung carcinoma (SCLC) 149
A new race against lung cancer 148
Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus 148
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 148
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients 148
Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents 147
EAGLES study: First-line bevacizumab in combination with chemotherapy in elderly patients with advanced, metastatic, non-squamous non-small cell lung cancer 146
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: Attempts to improve long-term outcome 145
Targeted therapies and immunotherapy in non-small-cell lung cancer 145
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) [Trattamento con Gefitinib nei pazienti anziani o con scarso performance status (PS), affetti da carcinoma polmonare non a piccole cellule (NSCLC)] 145
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 144
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 144
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: Analysis of 318 patients 144
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 144
Oxaliplatin doublets in non-small cell lung cancer: A literature review 143
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients 143
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? 141
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial 140
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer 140
Isolated cardiac metastasis from squamous cell esophageal cancer 138
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 138
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset 138
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 134
Totale 20.454
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.092
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.092
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.126 0 156 159 71 40 86 79 62 67 53 96 257
2022/20231.894 273 635 127 134 83 303 33 99 131 21 30 25
2023/20241.867 32 36 59 59 272 498 377 101 205 14 17 197
2024/20253.752 219 500 198 171 301 132 213 80 463 555 277 643
2025/20268.873 783 521 464 642 908 451 1.591 452 710 572 965 814
2026/2027689 354 335 0 0 0 0 0 0 0 0 0 0
Totale 23.846